A Phase 2 interventional study of LN-145 and LN-145 + pembrolizumab in Cervical Carcinoma, sponsored by Iovance Biotherapeutics, Inc.. Terminated at 43 sites in 8 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-25.
Sponsored by Iovance Biotherapeutics, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 834 studies in Uterine Cervical Neoplasms with a site in United States — 145 open to participants now, 219 under way, 6 of them phase 3. Uterine Cervical Neoplasms · United States.
Among the 834 studies in Uterine Cervical Neoplasms with a site in United States, this one is the 186th largest by enrollment of the 678 interventional ones that give a count, is one of 26 that started in 2017, is one of 165 in phase 2, and was the 429th registered.
2,368 studies on the registry are indexed under Uterine Cervical Neoplasms; 677 are open to participants now.
Browse Uterine Cervical Neoplasms studies →145 of the 834 studies in Uterine Cervical Neoplasms with a site in United States are open now. Recruiting first, the newest first:
Rutgers, The State University of New Jersey · Sites in United States
Ages 30–65 · Women only · Healthy volunteers
Florida A&M University · Sites in United States
Ages 21–65 · Women only · Healthy volunteers
City of Hope Medical Center · Sites in United States
Ages 18+ · Women only
Mark Bernard · Sites in United States
Ages 18–99
University of Florida · Sites in United States
Ages 25+ · Women only · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 474 Uterine Cervical Neoplasms studies recruiting now, 243 (51%) set no upper age limit and 191 (40%) stop at 75 or younger; 20 take children under 18; 69 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
834 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 242 · Phase 2 240 · Phase 3 45 · Phase 4 9
First in 1992; this study’s year is marked. 26 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 210 is above the median of 100 across 1,738 interventional studies indexed under Uterine Cervical Neoplasms.
Median enrollment 71 across the 678 interventional studies, 138 across the 124 observational. Of the 569 that completed or were terminated, 193 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
213 of 834 have an industry lead sponsor. The 10 most frequent:
Iovance Biotherapeutics, Inc. is the lead sponsor of 16 studies on the registry; 8 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 3 (50%) have results posted.
Iovance Biotherapeutics, Inc. has 1 study filed under Uterine Cervical Neoplasms — fewer than ten, so there is no comparison to draw.
87 of the studies in Uterine Cervical Neoplasms with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06079671Phase 3AstraZenecaStudy of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical) | 2027-11-26 |
| NCT02285192Memorial Sloan Kettering Cancer CenterPositron Lymphography Via Intracervical 18F-FDG Injection for Pre-surgical Lymphatic Mapping in Stage IB1 Cervical Cancer and High-grade Endometrial Cancer | 2026-11 |
| NCT05758688Abramson Cancer Center at Penn MedicinePROton Therapy for Post Surgical Treatment of GYNecologic Cancer | 2026-11 |
| NCT07574190University of South DakotaA Mobile Web App Intervention to Promote Cervical Cancer Screening | 2026-11 |
| NCT00579163Memorial Sloan Kettering Cancer CenterAscertainment of Peripheral Blood or Saliva Samples for Genetic Epidemiology Studies of Familial Cancers | 2026-12 |
Add all 87 to your calendar (.ics) → With an account.
Among the 834 studies in Uterine Cervical Neoplasms with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Prospective, multicenter, multiple cohort, open label, interventional study evaluating adoptive cell therapy (ACT) with autologous tumor infiltrating lymphocytes (TIL) infusion (LN-145), with or without pembrolizumab, followed by IL-2 after a non-myeloablative lymphodepletion (NMA-LD) preparative regimen for the treatment of participants with recurrent, metastatic, or persistent cervical carcinoma.
LN-145 is an adoptive cell transfer therapy that utilizes an autologous TIL manufacturing process, as originally developed by the NCI, for the treatment of participants with recurrent, metastatic, or persistent cervical carcinoma. The cell transfer therapy used in this study involves participants receiving a non-myeloablative lymphodepletion (NMA-LD) preparative regimen, followed by infusion of autologous TIL, with or without pembrolizumab, followed by the administration of a regimen of IL-2.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
To be eligible for the study, participants must meet ALL of the following criteria prior to participation:
Cohort 1 and Cohort 2: Progression during or following at least one, but no more than three, prior systemic chemotherapeutic treatments for recurrent, metastatic, or persistent cervical carcinoma
Cohort 2: Must also have previously received treatment with a (ie, PD-1, PD-L1]) in the setting of recurrent, metastatic, or persistent disease either as monotherapy or in combination (eg, in combination with chemotherapy or another immune agent)
Cohort 3 (United States only): Must have not received any therapies other than prior chemoradiation or surgery for loco-regional disease
Exclusion Criteria:
Participants who meet any of the following criteria are not eligible for participation in this study:
. Participants who have a history of to any component or of LN-145 or other study drugs:
Participants with symptomatic and/or untreated (of any size and any number)
Participants who are of the following protected classes will be excluded, including:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LN-145 monotherapy in participants who have progressed during or following systemic therapy; this cohort is no longer open for enrollment.
Biological: LN-145
LN-145 monotherapy in participants who have previously received a PD-1/PD-L1 checkpoint inhibitor either as monotherapy or combination therapy.
Biological: LN-145
LN-145 in combination with pembrolizumab in participants who have not received any therapies other than prior chemoradiation or surgery for loco-regional disease.
Biological: LN-145 + pembrolizumab
LN-145 monotherapy in previously enrolled participants who do not meet requirements for inclusion in the other study cohorts; this cohort is not open for enrollment.
Biological: LN-145
LN-145 monotherapy as a re-treatment.
Biological: LN-145
Drug pages: Lifileucel · Autologous Tumor Infiltrating Lymphocytes LN-145
A tumor sample is resected from each participant and cultured ex vivo to expand the population of tumor infiltrating lymphocytes.
Also known as: TIL, autologous tumor infiltrating lymphocytes
Drug pages: Lifileucel · Autologous Tumor Infiltrating Lymphocytes LN-145 · Pembrolizumab
A tumor sample is resected from each participant and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. The first dose of anti-PD-1 immunotherapy will be administered following tumor resection.
Also known as: TIL, autologous tumor infiltrating lymphocytes; pembrolizumab (anti-PD-1 immunotherapy)
Cohort 1 and 2: Objective Response Rate
To evaluate the efficacy of LN-145 in participants with recurrent, metastatic, or persistent cervical carcinoma based on the objective response rate (ORR) as assessed by the Investigator per Response Evaluation Criteria In Solid Tumors (RECIST v1.1) for target lesions based on imaging: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
Time frame: Up to 60 months
Cohort 3: Number of Participants With Adverse Events
To characterize the safety profile of LN-145 in combination with pembrolizumab in participants with recurrent, metastatic, or persistent cervical carcinoma as assessed by number of participants with adverse events.
Time frame: Up to 60 months
Cohort 4: Number of Participants With Adverse Events
To explore the safety profile of LN-145 in previously enrolled participants with recurrent, metastatic, or persistent cervical carcinoma as assessed by number of participants with adverse events.
Time frame: Up to 60 months
Cohort 4: Efficacy/Objective Response Rate
To explore the efficacy of LN-145 in previously enrolled participants with recurrent, metastatic, or persistent cervical carcinoma based on the objective response rate (ORR) as assessed by the Investigator per Response Evaluation Criteria In Solid Tumors (RECIST v1.1) for target lesions based on imaging: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
Time frame: Up to 60 months
Cohort 5: Number of Participants With Adverse Events
To explore the safety profile of LN-145 in re-treated participants with recurrent, metastatic, or persistent cervical carcinoma as assessed by number of participants with adverse events.
Time frame: Up to 60 months
Cohort 5: Efficacy/Objective Response Rate
To explore the efficacy of LN-145 in re-treated participants with recurrent, metastatic, or persistent cervical carcinoma based on the objective response rate (ORR) as assessed by the Investigator per Response Evaluation Criteria In Solid Tumors (RECIST v1.1) for target lesions based on imaging: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
Time frame: Up to 60 months
Cohort 1 and 2: Duration of Response
To evaluate the efficacy parameters of LN-145 in participants with recurrent, metastatic, or persistent cervical carcinoma by assessing duration of response (DOR) as assessed by the Investigator per Response Evaluation Criteria In Solid Tumors (RECIST v1.1) for target lesions based on imaging: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions. DOR is measured from the first time response (PR/CR) criteria are met until the first date of progression, or the participant expires.
Time frame: Up to 60 months
Cohort 1 and 2: Disease Control Rate
To evaluate the efficacy parameters of LN-145 in participants with recurrent, metastatic, or persistent cervical carcinoma by assessing disease control rate (DCR) as assessed by the Investigator per Response Evaluation Criteria In Solid Tumors (RECIST v1.1) for target lesions based on imaging: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Stable Disease (SD), \<20% increase nadir SLD (sum of longest diameter of target lesions). DCR is defined as the proportion of participants who have CR or PR or SD per RECIST v1.1.
Time frame: Up to 60 months
Cohort 1 and 2: Progression-Free Survival
To evaluate the efficacy parameters of LN-145 in participants with recurrent, metastatic, or persistent cervical carcinoma by assessing progression-free survival (PFS) as assessed by the Investigator per Response Evaluation Criteria In Solid Tumors (RECIST v1.1). Progression is defined using RECIST v1.1 as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
Time frame: Up to 60 months
Cohort 1 and 2: Overall Survival
To evaluate overall survival (OS) in participants with recurrent, metastatic, or persistent cervical carcinoma
Time frame: Up to 60 months
Cohort 1 and 2: Number of Participants With Adverse Events
To characterize the safety profile of LN-145 in participants with recurrent, metastatic, or persistent cervical carcinoma as assessed by number of participants with adverse events.
Time frame: Up to 60 months
Cohort 3: Objective Response Rate
To evaluate the efficacy of LN-145 in combination with pembrolizumab in participants with recurrent, metastatic, or persistent cervical carcinoma based on the objective response rate (ORR) as assessed by the Investigator per Response Evaluation Criteria In Solid Tumors (RECIST v1.1) for target lesions based on imaging: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
Time frame: Up to 60 months
Cohort 3: Duration of Response
To evaluate the efficacy of LN-145 in combination with pembrolizumab in participants with recurrent, metastatic, or persistent cervical carcinoma by assessing duration of response (DOR) as assessed by the Investigator per Response Evaluation Criteria In Solid Tumors (RECIST v1.1) for target lesions based on imaging: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions. DOR is measured from the first time response (PR/CR) criteria are met until the first date of progression, or the participant expires.
Time frame: Up to 60 months
Cohort 3: Disease Control Rate
To evaluate the efficacy of LN-145 in combination with pembrolizumab in participants with recurrent, metastatic, or persistent cervical carcinoma by assessing disease control rate (DCR) as assessed by the Investigator per Response Evaluation Criteria In Solid Tumors (RECIST v1.1) for target lesions based on imaging: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Stable Disease (SD), \<20% increase nadir SLD (sum of longest diameter of target lesions). DCR is defined as the proportion of participants who have CR or PR or SD per RECIST v1.1.
Time frame: Up to 60 months
Cohort 3: Progression-Free Survival
To evaluate the efficacy of LN-145 in combination with pembrolizumab in participants with recurrent, metastatic, or persistent cervical carcinoma by assessing progression-free survival (PFS) as assessed by the Investigator per Response Evaluation Criteria In Solid Tumors (RECIST v1.1). Progression is defined using RECIST v1.1 as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
Time frame: Up to 60 months
Cohort 3: Overall Survival
To evaluate overall survival (OS) in participants with recurrent, metastatic, or persistent cervical carcinoma.
Time frame: Up to 60 months
| Milestone | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Cohort 5 |
|---|---|---|---|---|---|
| Started | 100 | 62 | 32 | 16 | 0 |
| Participants infused with til | 74 | 42 | 26 | 10 | 0 |
| Completed | 7 | 0 | 1 | 1 | 0 |
| Not completed | 93 | 62 | 31 | 15 | 0 |
| Withdrew: Did not receive til | 26 | 20 | 6 | 6 | 0 |
| Withdrew: Death | 63 | 34 | 17 | 9 | 0 |
| Withdrew: Lost to follow-up | 2 | 3 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 2 | 4 | 1 | 0 | 0 |
| Withdrew: Study terminated by sponsor | 0 | 1 | 7 | 0 | 0 |
| Milestone | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Cohort 5 |
|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 6 |
| Participants infused with til | 0 | 0 | 0 | 0 | 2 |
| Completed | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 6 |
| Withdrew: Did not receive til | 0 | 0 | 0 | 0 | 4 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 2 |
To evaluate the efficacy of LN-145 in participants with recurrent, metastatic, or persistent cervical carcinoma based on the objective response rate (ORR) as assessed by the Investigator per Response Evaluation Criteria In Solid Tumors (RECIST v1.1) for target lesions based on imaging: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
| Participants | Cohort 1 | Cohort 2 |
|---|---|---|
| Cohort 1 and 2: Objective Response Rate | 15 | 5 |
To characterize the safety profile of LN-145 in combination with pembrolizumab in participants with recurrent, metastatic, or persistent cervical carcinoma as assessed by number of participants with adverse events.
| Participants | Cohort 3 |
|---|---|
| Cohort 3: Number of Participants With Adverse Events | 26 |
To explore the safety profile of LN-145 in previously enrolled participants with recurrent, metastatic, or persistent cervical carcinoma as assessed by number of participants with adverse events.
| Participants | Cohort 4 |
|---|---|
| Cohort 4: Number of Participants With Adverse Events | 10 |
To explore the efficacy of LN-145 in previously enrolled participants with recurrent, metastatic, or persistent cervical carcinoma based on the objective response rate (ORR) as assessed by the Investigator per Response Evaluation Criteria In Solid Tumors (RECIST v1.1) for target lesions based on imaging: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
| Participants | Cohort 4 |
|---|---|
| Cohort 4: Efficacy/Objective Response Rate | 2 |
To explore the safety profile of LN-145 in re-treated participants with recurrent, metastatic, or persistent cervical carcinoma as assessed by number of participants with adverse events.
| Participants | Cohort 5 |
|---|---|
| Cohort 5: Number of Participants With Adverse Events | 2 |
To explore the efficacy of LN-145 in re-treated participants with recurrent, metastatic, or persistent cervical carcinoma based on the objective response rate (ORR) as assessed by the Investigator per Response Evaluation Criteria In Solid Tumors (RECIST v1.1) for target lesions based on imaging: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
| Participants | Cohort 5 |
|---|---|
| Cohort 5: Efficacy/Objective Response Rate | 0 |
To evaluate the efficacy parameters of LN-145 in participants with recurrent, metastatic, or persistent cervical carcinoma by assessing duration of response (DOR) as assessed by the Investigator per Response Evaluation Criteria In Solid Tumors (RECIST v1.1) for target lesions based on imaging: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions. DOR is measured from the first time response (PR/CR) criteria are met until the first date of progression, or the participant expires.
| months | Cohort 1 | Cohort 2 |
|---|---|---|
| Cohort 1 and 2: Duration of Response | 6.8 (2.5 to NA) | 6.7 (4.2 to NA) |
To evaluate the efficacy parameters of LN-145 in participants with recurrent, metastatic, or persistent cervical carcinoma by assessing disease control rate (DCR) as assessed by the Investigator per Response Evaluation Criteria In Solid Tumors (RECIST v1.1) for target lesions based on imaging: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Stable Disease (SD), \<20% increase nadir SLD (sum of longest diameter of target lesions). DCR is defined as the proportion of participants who have CR or PR or SD per RECIST v1.1.
| Participants | Cohort 1 | Cohort 2 |
|---|---|---|
| Cohort 1 and 2: Disease Control Rate | 43 | 23 |
To evaluate the efficacy parameters of LN-145 in participants with recurrent, metastatic, or persistent cervical carcinoma by assessing progression-free survival (PFS) as assessed by the Investigator per Response Evaluation Criteria In Solid Tumors (RECIST v1.1). Progression is defined using RECIST v1.1 as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
| months | Cohort 1 | Cohort 2 |
|---|---|---|
| Cohort 1 and 2: Progression-Free Survival | 2.8 (2.3 to 4.1) | 2.8 (1.5 to 2.9) |
To evaluate overall survival (OS) in participants with recurrent, metastatic, or persistent cervical carcinoma
| months | Cohort 1 | Cohort 2 |
|---|---|---|
| Cohort 1 and 2: Overall Survival | 8.8 (6.7 to 11.4) | 8.2 (4.0 to 10.3) |
To characterize the safety profile of LN-145 in participants with recurrent, metastatic, or persistent cervical carcinoma as assessed by number of participants with adverse events.
| Participants | Cohort 1 | Cohort 2 |
|---|---|---|
| Cohort 1 and 2: Number of Participants With Adverse Events | 74 | 42 |
To evaluate the efficacy of LN-145 in combination with pembrolizumab in participants with recurrent, metastatic, or persistent cervical carcinoma based on the objective response rate (ORR) as assessed by the Investigator per Response Evaluation Criteria In Solid Tumors (RECIST v1.1) for target lesions based on imaging: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
| Participants | Cohort 3 |
|---|---|
| Cohort 3: Objective Response Rate | 13 |
To evaluate the efficacy of LN-145 in combination with pembrolizumab in participants with recurrent, metastatic, or persistent cervical carcinoma by assessing duration of response (DOR) as assessed by the Investigator per Response Evaluation Criteria In Solid Tumors (RECIST v1.1) for target lesions based on imaging: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions. DOR is measured from the first time response (PR/CR) criteria are met until the first date of progression, or the participant expires.
| months | Cohort 3 |
|---|---|
| Cohort 3: Duration of Response | NA (4.4 to NA) |
To evaluate the efficacy of LN-145 in combination with pembrolizumab in participants with recurrent, metastatic, or persistent cervical carcinoma by assessing disease control rate (DCR) as assessed by the Investigator per Response Evaluation Criteria In Solid Tumors (RECIST v1.1) for target lesions based on imaging: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Stable Disease (SD), \<20% increase nadir SLD (sum of longest diameter of target lesions). DCR is defined as the proportion of participants who have CR or PR or SD per RECIST v1.1.
| Participants | Cohort 3 |
|---|---|
| Cohort 3: Disease Control Rate | 23 |
To evaluate the efficacy of LN-145 in combination with pembrolizumab in participants with recurrent, metastatic, or persistent cervical carcinoma by assessing progression-free survival (PFS) as assessed by the Investigator per Response Evaluation Criteria In Solid Tumors (RECIST v1.1). Progression is defined using RECIST v1.1 as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
| months | Cohort 3 |
|---|---|
| Cohort 3: Progression-Free Survival | 6.2 (3.3 to NA) |
To evaluate overall survival (OS) in participants with recurrent, metastatic, or persistent cervical carcinoma.
| months | Cohort 3 |
|---|---|
| Cohort 3: Overall Survival | 27.7 (15.2 to 41.6) |
Collected over From enrollment to end of follow-up (up to 60 months). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1 | 63/74 (85.1%) | 31/74 (41.9%) | 74/74 (100%) |
| Cohort 2 | 34/42 (81%) | 20/42 (47.6%) | 42/42 (100%) |
| Cohort 3 | 17/26 (65.4%) | 18/26 (69.2%) | 26/26 (100%) |
| Cohort 4 | 9/10 (90%) | 7/10 (70%) | 10/10 (100%) |
| Cohort 5 | 2/2 (100%) | 1/2 (50%) | 2/2 (100%) |
| Event | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Cohort 5 |
|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 0/74 | 0/42 | 1/26 | 0/10 | 1/2 |
| VomitingGastrointestinal disorders | 1/74 | 0/42 | 2/26 | 1/10 | 1/2 |
| DehydrationMetabolism and nutrition disorders | 1/74 | 0/42 | 0/26 | 0/10 | 1/2 |
| Acute kidney injuryRenal and urinary disorders | 4/74 | 6/42 | 2/26 | 0/10 | 0/2 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 0/74 | 1/42 | 3/26 | 0/10 | 0/2 |
| ThrombocytopeniaBlood and lymphatic system disorders | 4/74 | 3/42 | 0/26 | 1/10 | 0/2 |
| Acute myocardial infarctionCardiac disorders | 0/74 | 0/42 | 0/26 | 1/10 | 0/2 |
| Cardiac failure congestiveCardiac disorders | 0/74 | 0/42 | 0/26 | 1/10 | 0/2 |
| Ventricular fibrillationCardiac disorders | 0/74 | 0/42 | 0/26 | 1/10 | 0/2 |
| Systemic inflammatory response syndromeGeneral disorders | 0/74 | 0/42 | 0/26 | 1/10 | 0/2 |
| Event | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Cohort 5 |
|---|---|---|---|---|---|
| ChillsGeneral disorders | 45/74 | 25/42 | 23/26 | 5/10 | 0/2 |
| NauseaGastrointestinal disorders | 19/74 | 3/42 | 22/26 | 1/10 | 0/2 |
| AnaemiaBlood and lymphatic system disorders | 49/74 | 24/42 | 20/26 | 7/10 | 1/2 |
| ThrombocytopeniaBlood and lymphatic system disorders | 39/74 | 26/42 | 15/26 | 7/10 | 1/2 |
| VomitingGastrointestinal disorders | 22/74 | 9/42 | 18/26 | 3/10 | 1/2 |
| FatigueGeneral disorders | 16/74 | 5/42 | 17/26 | 2/10 | 0/2 |
| NeutropeniaBlood and lymphatic system disorders | 26/74 | 7/42 | 14/26 | 6/10 | 0/2 |
| PyrexiaGeneral disorders | 41/74 | 13/42 | 14/26 | 6/10 | 0/2 |
| ConstipationGastrointestinal disorders | 9/74 | 5/42 | 15/26 | 0/10 | 1/2 |
| HypoxiaRespiratory, thoracic and mediastinal disorders | 20/74 | 6/42 | 15/26 | 2/10 | 0/2 |
The Safety Analysis Set is defined as participants who received TIL. Cohort 5 participants had progressed following the initial TIL treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are captured for retreatment in Cohort 5.
| Age, Categorical(Participants) | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Cohort 5 | Total |
|---|---|---|---|---|---|---|
| Initial Treatment — <=18 years | 0 | 1 | 0 | 0 | 0 | 1 |
| Initial Treatment — Between 18 and 65 years | 69 | 37 | 23 | 10 | 0 | 139 |
| Initial Treatment — >=65 years | 5 | 4 | 3 | 0 | 0 | 12 |
| Retreatment — <=18 years | 0 | 0 | 0 | 0 | 0 | 0 |
| Retreatment — Between 18 and 65 years | 0 | 0 | 0 | 0 | 2 | 2 |
| Retreatment — >=65 years | 0 | 0 | 0 | 0 | 0 | 0 |
| Age, Continuous(Years) | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Cohort 5 | Total |
|---|---|---|---|---|---|---|
| Initial Treatment | 44 (24 to 72) | 46.5 (18 to 72) | 46.5 (31 to 73) | 46.5 (38 to 61) | — | 45 (18 to 73) |
| Retreatment | — | — | — | — | 49.5 (43 to 56) | 49.5 (43 to 56) |
| Sex: Female, Male(Participants) | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Cohort 5 | Total |
|---|---|---|---|---|---|---|
| Initial Treatment — Female | 74 | 42 | 26 | 10 | 0 | 152 |
| Initial Treatment — Male | 0 | 0 | 0 | 0 | 0 | 0 |
| Retreatment — Female | — | — | — | — | 2 | 2 |
| Retreatment — Male | — | — | — | — | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Cohort 5 | Total |
|---|---|---|---|---|---|---|
| Initial Treatment — Hispanic or Latino | 5 | 7 | 4 | 1 | 0 | 17 |
| Initial Treatment — Not Hispanic or Latino | 60 | 35 | 22 | 7 | 0 | 124 |
| Initial Treatment — Unknown or Not Reported | 9 | 0 | 0 | 2 | 0 | 11 |
| Retreatment — Hispanic or Latino | 0 | 0 | 0 | 0 | 0 | 0 |
| Retreatment — Not Hispanic or Latino | 0 | 0 | 0 | 0 | 2 | 2 |
| Retreatment — Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Cohort 5 | Total |
|---|---|---|---|---|---|---|
| Initial Treatment — American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Initial Treatment — Asian | 4 | 2 | 3 | 0 | 0 | 9 |
| Initial Treatment — Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Initial Treatment — Black or African American | 2 | 3 | 0 | 0 | 0 | 5 |
| Initial Treatment — White | 58 | 33 | 23 | 9 | 0 | 123 |
| Initial Treatment — More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Initial Treatment — Unknown or Not Reported | 10 | 4 | 0 | 1 | 0 | 15 |
| Retreatment — American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Retreatment — Asian | 0 | 0 | 0 | 0 | 0 | 0 |
| Retreatment — Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Retreatment — Black or African American | 0 | 0 | 0 | 0 | 0 | 0 |
| Retreatment — White | 0 | 0 | 0 | 0 | 2 | 2 |
| Retreatment — More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Retreatment — Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Cohort 5 | Total |
|---|---|---|---|---|---|---|
| Netherlands | 8 | 0 | 0 | 0 | 0 | 8 |
| United States | 40 | 35 | 26 | 9 | 0 | 110 |
| United Kingdom | 7 | 0 | 0 | 0 | 0 | 7 |
| France | 4 | 0 | 0 | 1 | 0 | 5 |
| Switzerland | 3 | 1 | 0 | 0 | 0 | 4 |
| Germany | 6 | 1 | 0 | 0 | 0 | 7 |
| Spain | 6 | 5 | 0 | 0 | 0 | 11 |
| Region of Enrollment(Participants) | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Cohort 5 | Total |
|---|---|---|---|---|---|---|
| United States | — | — | — | — | 1 | 1 |
| Switzerland | — | — | — | — | 1 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jun 2017 to primary completion in Aug 2025, 98 months.
Results were first posted in Jul 2026, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Lifileucel · Autologous Tumor Infiltrating Lymphocytes LN-145 · Pembrolizumab
Iovance Biotherapeutics, Inc.